Cost-effectiveness of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome in Canada (OASIS-5)
Crossref DOI link: https://doi.org/10.1186/s12872-015-0175-1
Published Online: 2015-12-29
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Alfonso Ross Terres, Jorge
Lozano-Ortega, G.
Kendall, R.
Sculpher, M. J.
License valid from 2015-12-01